Business
Lobe Sciences to Present at Sequire Cannabis & Psychedelics Conference April 5, 2023
Vancouver, British Columbia--(Newsfile Corp. - April 4, 2023) -  Lobe Sciences Ltd. (CSE: LO...
About this update from Lobe Sciences Ltd
[{"type":"text","content":"Lobe Sciences to Present at Sequire Cannabis & Psychedelics Conference April 5, 2023Vancouver, British Columbia--(Newsfile Corp. - April 4, 2023) -  Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (\"Lobe\" or the \"Company\") a North American Biopharmaceutical company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today announced that Philip Young, CEO and Executive Chairman, will present at the SEQUIRE CANNABIS & PSYCHEDELICS CONFERENCE, April 5th at 10:00AM EDT.Registration for the event is accessible via the following link Sign up free.About Lobe Sciences Ltd.Lobe Sciences is a biopharmaceutical company focused on developing patient-friendly, easily administered medicines for orphan and rare diseases. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using sub-hallucinatory doses of our proprietary compounds targeting and treating orphan and rare diseases. Each of our New Chemical Entities, L-130 and L-131, are being developed to address unmet medical needs in patient populations where there are few, if any therapeutic options. For further information please contact: Lobe Sciences Ltd.Philip J Young, [email protected]: (949) 505-5623NEITHER THE CSE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.This does not constitute an offer to sell or a solicitation of offers to buy any securities.Forward Looking Statements This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as \"will\", \"may\", \"should\", \"anticipate\", \"expects\" and similar expressions. All statements other than statements of historical fact included in this news release (including, without limitation, statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, and the development of innovative devices and delivery mechanisms to improve mental health and wellness) are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future even...